Precision BioSciences (DTIL) Receives a Buy from William Blair

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Precision BioSciences (DTILResearch Report). The company’s shares closed last Tuesday at $13.79.

According to, Prasad is a 5-star analyst with an average return of 29.1% and a 64.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Precision BioSciences with a $14.75 average price target.

See today’s analyst top recommended stocks >>

Precision BioSciences’ market cap is currently $635.5M and has a P/E ratio of -5.60. The company has a Price to Book ratio of 9.96.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company’s propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.